HRMYHealthcare · BiotechnologyThe 12 Wall Street analysts covering Harmony Biosciences Holdings, Inc. hold a median 12-month price target of $50 — +43.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Harmony Biosciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (44): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HRMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +43.7% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | Needham | Reiterates | Buy | $50 |
| 13 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $55 |
| 12 Oct 2026 | Needham | Reiterates | Buy | $50 |
| 26 Aug 2026 | Wolfe Research | Initiates | Outperform | — |
| 26 Aug 2026 | Wolfe Research | Initiates | Outperform | $60 |
| 5 Aug 2026 | Truist Securities | Maintains | Hold | $29 → $34 |
| 5 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 4 Aug 2026 | Needham | Maintains | Buy | $45 → $50 |
| 4 Aug 2026 | Needham | Maintains | Buy | — |
| 31 July 2026 | Mizuho | Maintains | Outperform | — |
| 31 July 2026 | Mizuho | Maintains | Outperform | $50 → $51 |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $55 |
| 16 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2026 | Deutsche Bank | Maintains | Hold | — |
| 8 May 2026 | Truist Securities | Maintains | Hold | — |
| 25 Feb 2026 | B of A Securities | Maintains | Underperform | — |
| 25 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Feb 2026 | Needham | Maintains | Buy | — |
| 25 Feb 2026 | UBS | Maintains | Neutral | — |
| 11 Feb 2026 | UBS | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HRMY appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Harmony Biosciences Holdings, Inc. returned +12.1% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 53% of US stocks
Cheaper than 48% of US stocks
Cheaper than 40% of US stocks
Cheaper than 50% of US stocks
Higher than 78% of US stocks
Higher than 82% of US stocks
Higher than 88% of US stocks
Higher than 89% of US stocks
Higher than 81% of US stocks
Higher than 81% of US stocks
Higher than 94% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Harmony Biosciences Holdings, Inc. has a market value of $2.2B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $959.9M. The latest quarter grew 30.3% year on year.
Net income over the same four quarters: $181.3M, a 18.9% net margin.
Diluted earnings per share, trailing twelve months: $3.08.
Free cash flow in the twelve months to 30 June 2026: $354.9M.
Trailing P/E: 11.9×; forward P/E: 5.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Harmony Biosciences Holdings, Inc. employs 293 people — $3.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Harmony Biosciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of Harmony Biosciences Holdings, Inc.’s Q3 2026 earnings call. The excerpt provides no further details about the call.
Why it matters — The transcript may offer HRMY watchers information from the company’s quarterly earnings call, but the provided excerpt contains no call specifics.
Harmony Biosciences reported third-quarter net revenue of $269 million, compared with $239 million a year earlier, citing continued growth in demand for WAKIX. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.
Why it matters — The update gives HRMY watchers information on quarterly revenue growth and the company's expectations for WAKIX sales this year.
Harmony Biosciences reported Q3 earnings of $0.81 per share, below the Zacks Consensus Estimate of $1 per share. Earnings were $0.87 per share in the year-ago quarter.
Why it matters — The results show quarterly earnings missed the consensus estimate and were lower than a year earlier, details relevant to HRMY watchers.
Harmony Biosciences reported Q3 WAKIX net revenue of $269 million, driven by 400 net patient adds, and reiterated full-year guidance of $1.0 billion to $1.04 billion. The headline also reports strong multiple-ascending dose data for orexin agonist BP-205.
Why it matters — The update gives HRMY watchers information on WAKIX demand and revenue guidance, as well as clinical data for BP-205.
Zacks Investment Research says Harmony Biosciences lacks the combination of two key ingredients associated with a likely earnings beat in its upcoming report. The headline says Wall Street expects earnings growth.
Why it matters — HRMY watchers may note the article’s caution about the likelihood of an earnings beat ahead of the upcoming report.
The 12 Wall Street analysts covering Harmony Biosciences Holdings, Inc. have a median 12-month price target of $50, with estimates ranging from $30 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Harmony Biosciences Holdings, Inc., 8 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Harmony Biosciences Holdings, Inc. 75 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Harmony Biosciences Holdings, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +43.7% from the last close, and Ticker Nerd's factor model ranks Harmony Biosciences Holdings, Inc. 75 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Harmony Biosciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HRMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $70 over the next 12 months.
Harmony Biosciences Holdings, Inc. returned +12.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and other unmet medical needs.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Harmony Biosciences Holdings, Inc.’s Q3 2026 earnings call. The excerpt provides no further details about the call.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases and other unmet medical needs. The company’s portfolio centers on treatments for sleep-wake disorders and related neurological conditions, with a strong emphasis on patients whose options remain limited. Its marketed therapy, WAKIX, is designed for the treatment of excessive daytime sleepiness in adults with narcolepsy, reflecting the company’s focus on specialized neuroscience care. Harmony Biosciences also advances research programs in adjacent rare neurological and endocrine disorders, combining commercial operations with clinical development capabilities. Headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences plays a focused role in the biopharmaceutical market by addressing niche patient populations through targeted, science-driven therapies.
CEO Dr. Jeffrey M. Dayno M.D. · 293 employees · United States · https://www.harmonybiosciences.com
